Latest news with #PetrosGrivas
Medscape
9 hours ago
- Health
- Medscape
ASCO 2025: Impact of Therapeutic Advances in Prostate Cancer
Petros Grivas, MD, shares key updates from ASCO 2025, focusing on advances in prostate cancer across disease stages. He highlights promising results from the AMPLITUDE trial showing a radiographic progression-free survival benefit with niraparib plus abiraterone in patients with BRCA-mutated tumors and anticipated further data from the PSMAddition trial involving lutetium-PSMA. Additional discussions included prostate-specific antigen nadir as a prognostic marker, quality-of-life outcomes from the ARANOTE trial, and emerging therapies like BiTEs and theranostics for castration-resistant disease. He emphasizes the importance of somatic and germline testing in personalizing treatment and improving outcomes for both patients and their families.
Medscape
22-05-2025
- Health
- Medscape
ASCO 2025: Anticipating Key Innovations in Prostate Cancer
Petros Grivas, MD, PhD, expresses great enthusiasm for the 2025 ASCO Annual Meeting, highlighting its wealth of clinical trial data, educational sessions, and real-world insights. He is particularly excited about new findings in prostate cancer, including the AMPLITUDE trial on PARP inhibitors and updates from the IRONMAN registry. He also emphasizes the importance of genomic testing in patient care and looks forward to data on its real-world utilization and potential barriers. Additional highlights include emerging therapeutics like bispecific antibodies and radioligand therapies, including updates on lutetium-PSMA for advanced prostate cancer.
